New no-donors with antithrombotic and vasodilating activities, X: Antiplatelet and antithrombotic effects of 3-methylsydnone-5-nitrosimine (RE 2047) in combination with ASA, pentoxifylline, and ticlopidine.
The combined effects of the NO-donor RE 2047 with ASA, pentoxifylline, ticlopidine or BM 14515 were determined in vitro (Born-test) and in vivo (rat thrombosis model). The inhibitory effects on platelet aggregation as well as the inhibition of thrombus formation in vivo were over additive and over independent. The combination of 10 mg/kg RE 2047 with the same dose of ASA in arterioles (A) showed 70% inhibition of thrombosis (venoles (V): 40%). The respective values for 10 mg/kg RE 2047 and 10 mg/kg pentoxifylline are 70% (A) and 35% (V). It is concluded that NO-donors in principle are compounds suitable for the combination with antithrombotic drugs of different mechanism of action.
Rehse
K
K
Institut für Pharmazie, Freien Universität Berlin.
Ciborski
T
T
D000818:Animals; D001241:Aspirin / Q000494:pharmacology; D004357:Drug Synergism; D005343:Fibrinolytic Agents / Q000494:pharmacology*; D010431:Pentoxifylline / Q000494:pharmacology; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D051381:Rats; D013558:Sydnones / Q000494:pharmacology*; D013988:Ticlopidine / Q000494:pharmacology
C092610:3-methylsydnone-5-nitrosimine; D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D013558:Sydnones; D013988:Ticlopidine; D001241:Aspirin; D010431:Pentoxifylline